Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

LM, Ward; F, Rauch; MP, Whyte; J, D'Astous; PE, Gates; D, Grogan; EL, Lester; RE, McCall; TA, Pressly; JO, Sanders; PA, Smith; RD, Steiner; E, Sullivan; G, Tyerman; DL, Smith-Wright; N, Verbruggen; N, Heyden; A, Lombardi; FH, Glorieux

doi:10.1210/jc.2010-0636

Public

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

Shared by NobleBlocks on Nov 24, 2010 • 12:00 AM UTC

Authors:

Ward LM

Rauch F

Whyte MP

Abstract

Context Information on the use of oral bisphosphonate agents to treat pediatric osteogenesis imperfecta (OI) is limited.Objective The objective of the investigation was to study the efficacy and safety of daily oral alendronate (ALN) in children with OI.Design and participants We conducted a multice...

Discussions